Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Behavior and Therapy Resistance [ChIP-Seq]

ABSTRACT: Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Behavior and Therapy Resistance [ChIP-Seq]

PROVIDER: PRJNA1220676 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Behavior and Therapy Resistance [scRNA-seq]

Project description:Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Be-havior and Therapy Resistance

2025-08-21 | GSE288878 | GEO

Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Behavior and Therapy Resistance

Project description:Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Behavior and Therapy Resistance

| PRJNA1219634 | ENA

Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Behavior and Therapy Resistance [CRISPR Screen]

Project description:Overall, the LNCaP line has served as a remarkably versatile PC model, though the molecular characteristics of several important substrains have not been established nor compared in a systematic manner. In this study, we used genome-scale approaches to characterize the genomic and transcriptomic features of the parental LNCaP_FGC line, and a spectrum of 12 derivative models that have been deployed for studies of PC. These studies provide insights into the biochemical features that endow PC with the potential to resist AR-directed therapy and identify features that may underlie the metastatic and treatment resistant phenotypes observed in patients. An important but under-appreciated feature of LNCaP concerns the remarkable heterogeneity of the original LNCaP isolate and the current LNCaP_FGC line which was never subjected to clonal selection. This feature, coupled with the inherent DNA mismatch repair deficiency and genomic instability, has produced a remarkable spectrum of sublines that have provided important insights into PC pathobiology, but also challenge reproducibility and the accurate interpretation of experimental findings.

2025-08-21 | GSE289398 | GEO

Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Behavior and Therapy Resistance [ChIP-Seq]

2025-08-21 | GSE289031 | GEO

Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Behavior and Therapy Resistance [RNA-seq]

2025-08-21 | GSE288591 | GEO

Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Behavior and Therapy Resistance [ATAC-seq]

2025-08-21 | GSE288843 | GEO

Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Behavior and Therapy Resistance [RNA-seq]

Project description:Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Behavior and Therapy Resistance [RNA-seq]

| PRJNA1218647 | ENA

Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Behavior and Therapy Resistance [ATAC-seq]

Project description:Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Behavior and Therapy Resistance [ATAC-seq]

| PRJNA1219600 | ENA

Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Behavior and Therapy Resistance [CRISPR Screen]

Project description:Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Behavior and Therapy Resistance [CRISPR Screen]

| PRJNA1222853 | ENA

Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Behavior and Therapy Resistance [scRNA-seq]

Project description:Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Behavior and Therapy Resistance [scRNA-seq]

| PRJNA1219657 | ENA